Lineage Cell Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
LCTX$1.04-3.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss attributable to Lineage | $(4,812) | $(4,139) |
| Net income (loss) attributable to noncontrolling interest | 23 | (4) |
| Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc. to net cash used in operating activities: | ||
| Issuance costs for common stock warrant liabilities | — | 183 |
| (Gain) loss on marketable equity securities, net | (24) | 5 |
| Accretion of income on marketable debt securities | (163) | (10) |
| Depreciation and amortization expense | 188 | 164 |
| Change in right-of-use assets and liabilities | (8) | (11) |
| Stock-based compensation | 1,172 | 1,217 |
| Change in fair value of warrant liability | (2,324) | (2,305) |
| Foreign currency remeasurement | (24) | 282 |
| Loss on disposal of assets | 12 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 154 | 424 |
| Prepaid expenses and other current assets | 434 | 692 |
| Accounts payable and accrued liabilities | (1,711) | (105) |
| Deferred revenue | (995) | (1,279) |
| Net cash used in operating activities | (8,078) | (4,886) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of marketable debt securities | (8,236) | — |
| Maturities of marketable debt securities | 5,965 | 2,000 |
| Purchase of equipment | (55) | (97) |
| Net cash (used in) provided by investing activities | (2,326) | 1,903 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from employee options exercised | 227 | — |
| Proceeds from exercise of warrants | 5,388 | — |
| Common shares received and retired for employee taxes paid | (40) | (15) |
| Proceeds from sale of common shares with warrants under registered direct financing, net of offering costs | — | 5,297 |
| Payment of financed insurance premium | — | (224) |
| Payment of finance lease liabilities | (14) | (14) |
| Net cash provided by financing activities | 5,561 | 5,044 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (5) | (73) |
| NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | (4,848) | 1,988 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | ||
| At beginning of the period | 41,324 | 46,354 |
| At end of the period | $36,476 | $48,342 |
| SUPPLEMENTAL DISCLOSURES: | ||
| Cash paid for interest | $1 | $14 |
| SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES: | ||
| Property and equipment expenditures in accounts payable | $70 | $4 |
| Financing costs in accounts payable and accrued liabilities | $— | $65 |
| Fair value of warrant liability recognized upon issuance in registered direct financing | $— | $2,205 |
| Derivative warrant liability reclassified to equity on exercise of warrants | $7,442 | $— |
| RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD: | ||
| Cash and cash equivalents | $35,939 | $47,886 |
| Restricted cash included in deposits and other long-term assets (see Note 13 (Commitments and Contingencies)) | 537 | 456 |
| Total cash, cash equivalents, and restricted cash | $36,476 | $48,342 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.